Adamas Pharmaceuticals, Inc. Common Stock Follow-On Offering
Davis Polk advised the joint book-running managers in connection with a $124.5 million SEC-registered follow-on offering of 3,000,000 shares of common stock of Adamas Pharmaceuticals, Inc…